{"id":"NCT02753127","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer","officialTitle":"A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2020-04-28","completion":"2021-05-12","firstPosted":"2016-04-27","resultsPosted":"2022-04-26","lastUpdate":"2023-11-15"},"enrollment":1253,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Napabucasin","otherNames":["BBI-608","BBI608","BB608"]},{"type":"DRUG","name":"Fluorouracil","otherNames":["5-FU","Carac","Efudex","Fluoroplex","Adrucil"]},{"type":"DRUG","name":"Leucovorin","otherNames":["Folinic Acid"]},{"type":"DRUG","name":"Irinotecan","otherNames":["Camptosar"]},{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]}],"arms":[{"label":"Napabucasin plus FOLFIRI","type":"EXPERIMENTAL"},{"label":"FOLFIRI","type":"ACTIVE_COMPARATOR"}],"summary":"This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Randomization to Date of Death from any cause or database cutoff date (28 Apr 2020) (Approximately 43 months)","effectByArm":[{"arm":"Napabucasin + FOLFIRI ± Bevacizumab","deltaMin":14.29,"sd":null},{"arm":"FOLFIRI ± Bevacizumab","deltaMin":13.83,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3629"},{"comp":"OG000 vs OG001","p":"0.3782"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":211,"countries":["United States","Australia","Belgium","Canada","China","Czechia","France","Germany","Hong Kong","Israel","Italy","Japan","Netherlands","Singapore","South Korea","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":234,"n":622},"commonTop":["Diarrhoea","Nausea","Fatigue","Vomiting","Decreased Appetite"]}}